Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;45(9):860-867.
doi: 10.1016/j.clinthera.2023.04.005. Epub 2023 May 15.

Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review

Affiliations

Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review

Andre Lucas Ribeiro et al. Clin Ther. 2023 Sep.

Abstract

Purpose: In 2020, the International League of Associations for Rheumatology published recommendations for managing psoriatic arthritis (PsA), aiming to adapt the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and the European Alliance of Associations for Rheumatology recommendations to low-income countries. At that time, the paucity of clinical studies examining the management of patients with PsA in Latin America was remarked on by the international working group. Therefore, the primary objective of this systematic literature review was to investigate the main challenges in managing PsA in Latin America as described in recent publications.

Methods: A systematic literature review of trials reporting at least one challenge/difficulty in the management of PsA in Latin America was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. References published in the PubMed, EMBASE, and LILACS (Latin American and Caribbean Health Sciences Literature) databases between 1980 and February 2023 were included. The selection of references was conducted independently by 2 researchers in the Rayyan Qatar Computing Research Institute program. Two other reviewers independently extracted data. All challenges were noted and categorized into domains. Data analysis was descriptive.

Findings: The search strategy yielded 2085 references, with 21 studies included in the final analysis. Most studies were conducted in Brazil (66.6%; n = 14) and were observational studies (100%; N = 21). Difficulties faced by PsA patients and physicians included the high incidence of opportunistic infections (described in 42.8% of the publications; n = 9), followed by nonadherence to therapy, discordance between patients and physicians regarding remission rates, low drug persistence, limited access to disease-modifying antirheumatic drugs, issues related to the storage of biologic drugs, elevated cost of biologic drugs, limited access to medical care, diagnostic delay, and the individual- and country-level impact of socioeconomic factors on work- and health-related outcomes.

Implications: Challenges in the management of PsA in Latin America extend beyond the care of opportunistic infections, encompassing several other socioeconomic factors. More research is needed to better understand the peculiarities of treating PsA in Latin America to improve patient care. PROSPERO identifier: CRD42021228297.

Keywords: Latin America; adherence; challenges of treatment; medical care; psoriatic arthritis; unmet needs.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr Kohem has received grant support from Novartis; was a speaker for AbbVie, Janssen, UCB, Pfizer, and Novartis; and received support for attending meetings from Novartis, Janssen, AbbVie, Amgen, Roche, and AstraZeneca. Dr Coates has received grant support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; has received consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, MoonLake, Novartis, Pfizer, and UCB; was a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer, and UCB; and received support for attending meetings from Novartis and Janssen. Dr Monticielo was a speaker for AbbVie, AstraZeneca, Boehringer Ingelheim, GSK, Janssen, and Novartis; and received support for attending meetings from AstraZeneca and Janssen. Dr Palominos has received grant support from Pfizer and Novartis; and was a speaker for AbbVie, UCB, Novartis, and Janssen. The authors have indicated that they have no other conflicts of interest regarding the content of this article.

Publication types

MeSH terms